Pegylated-Interferon Alpha Therapy for Treatment-Experienced Chronic Hepatitis B Patients
暂无分享,去创建一个
Ming‐Lung Yu | C. Peng | H. Lai | M. Yeh | Chung‐Feng Huang | C. Dai | Zu-Yau Lin | Jee-Fu Huang | W. Chuang | Shinn-Cherng Chen | M. Hsieh | M. Yu | Jee‐Fu Huang
[1] P. Marcellin,et al. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype. , 2013, Journal of hepatology.
[2] C. Chu,et al. Off‐therapy durability of response to entecavir therapy in hepatitis B e antigen‐negative chronic hepatitis B patients , 2013, Hepatology.
[3] V. Wong,et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis , 2013, Hepatology.
[4] Yoshiyuki Suzuki,et al. Long‐term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection , 2013, Hepatology.
[5] R. Fontana,et al. Meta‐analysis: the impact of oral anti‐viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B , 2013, Alimentary pharmacology & therapeutics.
[6] P. Marcellin,et al. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients , 2013, Hepatology International.
[7] P. Lampertico,et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. , 2012, Journal of hepatology.
[8] P. Marcellin,et al. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients , 2012, Hepatology International.
[9] C. Peng,et al. Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa‐2a in HBeAg‐negative chronic hepatitis B , 2012, Alimentary pharmacology & therapeutics.
[10] P. Marcellin,et al. Shorter durations and lower doses of peginterferon alfa‐2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C , 2011, Hepatology.
[11] P. Marcellin,et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. , 2011, Journal of hepatology.
[12] F. Liu,et al. Poor durability of lamivudine effectiveness despite stringent cessation criteria: A prospective clinical study in hepatitis B e antigen‐negative chronic hepatitis B patients , 2011, Journal of gastroenterology and hepatology.
[13] G. Wong,et al. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B , 2010, Alimentary pharmacology & therapeutics.
[14] C. Boucher,et al. Prediction of sustained response to peginterferon alfa‐2b for hepatitis B e antigen–positive chronic hepatitis B using on‐treatment hepatitis B surface antigen decline , 2010, Hepatology.
[15] Lai Wei,et al. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa‐2b in HBeAg‐positive patients , 2010, Journal of gastroenterology and hepatology.
[16] H. Janssen,et al. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. , 2010, Gastroenterology.
[17] T. Asselah,et al. Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients , 2009, Hepatology.
[18] P. Marcellin,et al. Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa‐2a in HBeAg‐negative chronic hepatitis B , 2009, Hepatology.
[19] A. Cross,et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. , 2006, The New England journal of medicine.
[20] Thomas Berg,et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. , 2005, The New England journal of medicine.
[21] P. Marcellin,et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. , 2004, The New England journal of medicine.
[22] M. Mizokami,et al. Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns , 1999, FEBS letters.
[23] C. Chu,et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. , 2007, Journal of hepatology.
[24] Ding‐Shinn Chen,et al. Hepatitis B Virus Infection , 2007 .